From the article:

An experimental mRNA vaccine allowed people with high-risk melanoma to live longer, cancer-free, the pharmaceutical companies Moderna and Merck announced Wednesday.

[...]

In the late-stage trial of 1,137 people with high-risk melanoma who underwent surgery to have their cancer removed, those who received the personalized cancer vaccine, called intismeran, along with an immunotherapy drug called Keytruda were less likely to see their cancer recur or spread compared with those who received just Keytruda.

[...]

The study is the most advanced of a number of trials testing the approach against a variety of cancers, including lung, bladder, kidney and pancreatic cancer. While small trials have shown the promise of the approach, the Moderna and Merck trial was seen as a bellwether in demonstrating the technology — and a first step toward transforming cancer care with treatments that are individualized to a person’s tumor and that may ultimately be able to stay ahead of it as it changes.